Sinha, Vikram

Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA public workshop on PBPK

Wagner, C., Zhao, P., Pan, Y., Hsu, V, Grillo, J., Huang, S., & Sinha, V (2015) · CPT: Pharmacometrics & Systems Pharmacology

Pharmaceutical studies and practicesStatistical Methods in Clinical Trials

Cited by 276

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation

Lala, M., Li, T. R., de Alwis, D. P., Sinha, V., Mayawala, K., Yamamoto, N., Siu, L. L., Chartash, E., Aboshady, H., & Jain, L. (2020) · European Journal of Cancer

Cancer Immunotherapy and BiomarkersPharmaceutical studies and practices

Cited by 165

Predicting the effect of cytochrome P450 inhibitors on substrate drugs: Analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration

Wagner, C., Pan, Y., Hsu, V., Grillo, J. A., Zhang, L., Reynolds, K. S., Sinha, V., & Zhao, P. (2015) · Clinical Pharmacokinetics

Pharmacogenetics and Drug MetabolismPharmaceutical studies and practices

Cited by 148

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes

Rosenstock, J., Bergenstal, R. M., Blevins, T. C., Morrow, L. A., Prince, M. J., Qu, Y., Sinha, V. P., Howey, D. C., & Jacober, S. J. (2013) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 96

Fluoxetine Pharmacokinetics in Pediatric Patients

Wilens, T. E., Cohen, L., Biederman, J., Abrams, A., Neft, D., Faird, N., & Sinha, V. (2002) · Journal of Clinical Psychopharmacology

Pharmaceutical studies and practicesPharmacogenetics and Drug Metabolism

Cited by 64